<DOC>
	<DOCNO>NCT00085488</DOCNO>
	<brief_summary>RATIONALE : Vaccines make patient 's dendritic cell tumor cell may make body build immune response kill tumor cell . PURPOSE : This phase I trial study side effect best dose vaccine therapy treat patient stage III stage IV melanoma .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Stage III Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine dose-limiting toxicity maximum tolerate dose autologous dendritic cell pulse autologous tumor cell lysate patient stage III IV melanoma . - Determine safety tolerability therapy patient . Secondary - Determine immune response , term type degree T-cell proliferation delayed-type hypersensitivity response , patient treat therapy . OUTLINE : This dose-escalation , pilot study . Patients undergo leukapheresis collection peripheral blood mononuclear cell ( PBMC ) day -9 , 19 , 47 . Autologous dendritic cell ( DC ) prepare autologous PBMC expose sargramostim ( GM-CSF ) , interleukin-4 , tumor necrosis factor alpha pulse autologous tumor cell lysate . Patients receive autologous tumor cell lysate-pulsed DC IV 5-10 minute day 0 , 28 , 56 . Cohorts 3-6 patient receive escalate dos autologous tumor cell lysate-pulsed DC maximum tolerate dose ( MTD ) determine . The MTD define dose 33 % patient experience dose-limiting toxicity . Patients follow day 84 every 3 month thereafter . PROJECTED ACCRUAL : A total 3-20 patient accrue study within 3-20 month .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm melanoma Stage III ( lymph node intransit metastasis ) IV ( systemic metastasis ) disease Patients relapsed disease OR fail prior immunotherapy chemotherapy eligible ( trial restrict relapsed refractory disease ) Tumor tissue available properly store lysate preparation PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 60100 % Life expectancy At least 12 week Hematopoietic Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 75,000/mm^3 Hepatic AST ≤ 2 time upper limit normal ( ULN ) ( 3 time ULN liver metastasis ) Bilirubin ≤ 2 time ULN Hepatitis B surface antigen negative Hepatitis C negative Renal Creatinine ≤ 2.0 time ULN Immunologic No active infection No history autoimmune disease , include follow : Inflammatory bowel disease Systemic lupus erythematosus Scleroderma Rheumatoid arthritis Multiple sclerosis No allergy aminoglycosides streptomycin HIV negative Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No significant comorbid illness No malignancy within past 5 year except nonmelanoma skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics At least 10 day since prior immunotherapy Chemotherapy See Disease Characteristics Endocrine therapy At least 6 week since prior steroid therapy No concurrent corticosteroid Radiotherapy At least 10 day since prior radiotherapy No concurrent radiotherapy Surgery At least 10 day since prior surgery Prior diagnostic palliative surgery allow provide patient fully recover Other No concurrent immunosuppressive potentially immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2005</verification_date>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
</DOC>